Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:CKI NASDAQ:GBT TSE:TRZ CVE:ZMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCKIClarkeC$30.00-4.8%C$28.46C$20.73▼C$36.50C$418.48M1.182,610 shs1,734 shsGBTGlobal Blood Therapeutics$68.49$68.47$21.65▼$73.02$4.62B0.452.07 million shs74 shsTRZTransat A.T.C$2.73+2.6%C$2.67C$1.41▼C$3.00C$108.41M1.573,184 shs42,582 shsZMAZoomAway TechnologiesC$0.07+27.3%C$0.07C$0.03▼C$0.09C$1.35M1.5519,408 shs8,870 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCKIClarke+1.61%-3.08%+10.53%+40.81%+31.25%GBTGlobal Blood Therapeutics0.00%0.00%0.00%0.00%0.00%TRZTransat A.T.-3.62%-2.21%+1.92%+59.28%+40.00%ZMAZoomAway Technologies0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCKIClarkeN/AN/AN/AN/AN/AN/AN/AN/AGBTGlobal Blood Therapeutics0.2732 of 5 stars0.00.00.04.00.00.00.6TRZTransat A.T.0.1241 of 5 stars0.80.01.70.01.10.00.0ZMAZoomAway TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCKIClarke 0.00N/AN/AN/AGBTGlobal Blood Therapeutics 0.00N/AN/AN/ATRZTransat A.T. 1.60ReduceC$2.61-4.40% DownsideZMAZoomAway Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TRZ, ZMA, CKI, and GBT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025TRZTransat A.T.TD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuyC$4.75 ➝ C$5.506/13/2025TRZTransat A.T.ScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperformC$1.75 ➝ C$2.006/6/2025TRZTransat A.T.TD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-BuyC$1.75 ➝ C$4.756/6/2025TRZTransat A.T.National BanksharesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperformC$1.50 ➝ C$1.756/6/2025TRZTransat A.T.ScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetUnderperformC$1.25 ➝ C$1.755/28/2025TRZTransat A.T.National BanksharesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetUnderperformC$1.50(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCKIClarkeC$80.24M5.22C$0.73 per share41.01C$18.32 per share1.64GBTGlobal Blood Therapeutics$194.75M23.73N/AN/A$3.05 per share22.46TRZTransat A.T.C$3.36B0.03C$9.11 per share0.30C($22.89) per share-0.12ZMAZoomAway Technologies-C$1.62K-835.25C$0.00 per share17.73C($0.34) per share-0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCKIClarkeC$23.83MC$1.7117.56∞N/A29.70%10.04%2.83%N/AGBTGlobal Blood Therapeutics-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/ATRZTransat A.T.-C$116.59M-C$2.92N/A∞N/A-3.47%12.83%-1.38%N/AZMAZoomAway Technologies-C$1.22M-C$0.05N/A∞N/A-298.84%N/A-352.79%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCKIClarkeC$0.401.33%N/A23.41%N/AGBTGlobal Blood TherapeuticsN/AN/AN/AN/AN/ATRZTransat A.T.N/A4.81%N/AN/AN/AZMAZoomAway TechnologiesN/A6.65%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCKIClarkeN/AN/A0.11GBTGlobal Blood Therapeutics4.926.886.17TRZTransat A.T.-241.600.810.76ZMAZoomAway TechnologiesN/A0.010.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCKIClarke12.81%GBTGlobal Blood TherapeuticsN/ATRZTransat A.T.27.19%ZMAZoomAway Technologies55.19%Insider OwnershipCompanyInsider OwnershipCKIClarke76.18%GBTGlobal Blood Therapeutics4.90%TRZTransat A.T.0.04%ZMAZoomAway Technologies6.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCKIClarke55013.95 millionN/ANot OptionableGBTGlobal Blood Therapeutics45767.48 million64.17 millionOptionableTRZTransat A.T.5,00039.71 millionN/ANot OptionableZMAZoomAway TechnologiesN/A19.33 millionN/ANot OptionableTRZ, ZMA, CKI, and GBT HeadlinesRecent News About These CompaniesZoomAway Technologies Inc.: Zoomaway Announces Two Changes to Board of DirectorsJanuary 24, 2025 | finanznachrichten.deYahoo Tech | Technology News, Updates, Reviews & StoriesOctober 31, 2024 | yahoo.comThe Power of ZMA: Unlocking Better Sleep and Recovery for AthletesOctober 17, 2024 | healthtechzone.comHTurkey unveils ZMA-X: Revolutionizing robotic warfareOctober 3, 2024 | msn.comTurkish innovation: ZMA-X combat robot unveiled at teknofestOctober 3, 2024 | msn.comZoomAway Technologies: Top 10 Undervalued Travel & Leisure Industry Stocks (ZMA)May 7, 2024 | theglobeandmail.comZoomAway Technologies Inc.: ZoomAway Announces Proposed Change of Business to Investment IssuerMay 6, 2024 | finanznachrichten.deCanadian Investment Regulatory Organization Trading Halt - ZMAMay 6, 2024 | ca.finance.yahoo.comZoomAway Technologies Full Year 2023 Earnings: US$0.039 loss per share (vs US$0.11 loss in FY 2022)May 2, 2024 | finance.yahoo.comPool Safe: Top 10 Undervalued Consumer Cyclical Sector Stocks on TSX-V (POOL)February 20, 2024 | theglobeandmail.comZoomAway Technologies Inc. (ZMA.V)November 27, 2023 | ca.finance.yahoo.comZoomAway Closes Private PlacementNovember 21, 2023 | finance.yahoo.comZoomAway Technologies Inc.: ZoomAway Closes Private PlacementNovember 20, 2023 | finanznachrichten.deZoomAway Technologies Inc.: ZoomAway Announces Proposed Private PlacementNovember 6, 2023 | finanznachrichten.deZoomAway Announces Proposed Private PlacementNovember 6, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - ZMAOctober 25, 2023 | finance.yahoo.comZoomAway Provides Corporate Update And Announces Resumption Of TradingOctober 24, 2023 | finance.yahoo.comZMA.V - ZoomAway Technologies Inc.June 24, 2023 | ca.finance.yahoo.comZoomAway Technologies Stock (OTC:ZMWYF), Analyst Ratings, Price Targets, PredictionsOctober 29, 2022 | benzinga.comZoomAway Technologies Inc.: ZoomAway has Entered into Binding Letter of Intent to Acquire Large Ontario-Based Retailer and will Spin Out Travel AssetsApril 12, 2022 | finanznachrichten.deMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy These 3 Market-Beaters Are Backing Up Their Buyback TrucksBy Leo Miller | August 4, 2025If Qualcomm Holds $145, Its Next Move Could Be MassiveBy Sam Quirke | August 12, 20253 Dividend Stocks Raising Payouts—and Backing It Up With ResultsBy Gabriel Osorio-Mazilli | August 10, 2025NVIDIA: A Major Indicator Just Flashed Sell, But Should You?By Sam Quirke | July 30, 20253 Trucking Stocks Getting Big Analyst Upgrades NowBy Gabriel Osorio-Mazilli | August 6, 2025TRZ, ZMA, CKI, and GBT Company DescriptionsClarke TSE:CKIC$30.00 -1.50 (-4.76%) As of 03:39 PM EasternClarke Inc. is a private equity and venture capital firm specializing in investments in middle market, turnaround, PIPEs, bridge financing, recapitalization, and buyout companies. It invests in undervalued or underperforming businesses with hard assets. It invests in companies, securities or other assets such as real estate, which can be public or private entities. The firm primarily invests equity, debt and other securities. It invests in industries that have hard assets, including manufacturing, industrial, energy, materials, and real estate businesses. The firm invests in debt and equity securities of companies engaged in the oil and gas industry. It prefers to purchase well-priced equity securities rather than well-priced debt securities, and securities of oil service firms rather than E&P firms. The firm primarily invests in companies in Canada and United states of America. It seeks active involvement in the governance and/or management of the company it invests in. The firm may participate in Portfolio Company's board of directors. It makes balance sheet investments. Clarke Inc. was founded in 1997 and is based in Halifax, Canada.Global Blood Therapeutics NASDAQ:GBTGlobal Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.Transat A.T. TSE:TRZC$2.73 +0.07 (+2.63%) As of 04:00 PM EasternTransat A.T. Inc is a Canadian company that specializes in the organization, marketing, and distribution of holiday travel in the tourism industry. The company offers vacation packages, hotel stays, and air travel under the Transat and Air Transat brands. The company's core business consists of tour operators based in Canada that are vertically integrated with its other services of air transportation, distribution through a dynamic travel agency network, value-added services at travel destinations, and accommodations. Its geographical segments include the Transatlantic, Americas, and others.ZoomAway Technologies CVE:ZMAC$0.07 +0.02 (+27.27%) As of 05/6/2024ZoomAway Technologies Inc., an online travel company, provides tools and information to research, plan, book, and experience travel and destination services for business and leisure travelers. Its flagship project is ZoomedOUT, a travel, social, and gaming platform. The company was formerly known as ZoomAway Travel Inc. and changed its name to ZoomAway Technologies Inc. in April 2021. ZoomAway Technologies Inc. was incorporated in 1987 and is headquartered in Reno, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Palantir is Selling Off, BigBear.ai Could Be Your Hedge ASML Has Entered Buy Territory, But Only For Patient Investors Lowe’s Builds Value for Investors: Still a Good Buy in 2025 Target: Missing the Mark in 2025—Downtrend May Continue Toll Brothers: A Great Buy and Hold Stock With Risks in 2025 Amazon Stock Sets Up for Breakout After Bullish Crossover Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access